Cardiol Therapeutics Inc Class A faced a significant downturn in its stock performance, raising concerns among investors.
In yesterday's trading session, Cardiol Therapeutics Inc Class A (CRDL.TO) saw its stock price drop by 5.91%, closing at CA$2.23. This decline comes despite the company's recent progress in clinical trials and financial maneuvers aimed at strengthening its position in the market.
Advertisement
Cardiol Therapeutics Inc Class A
CRDL.TO
CRDL.TO
Cardiol Therapeutics Inc Class A
WealthAwesomeMarket cap
$270.97M
52W high
$3.23
52W low
$1.23
1W change
-8.23%
Beta
0.61
Analyst Price Targets
Based on analyst covering CRDL · as of Sep 17, 2026
Wall Street analysts forecast CRDL stock price to rise 284.6% over the next 12 months.
Consensus
BullishBased on avg. target vs last close (formal rating unavailable for Canadian listings)
Avg. Target
C$6.00
+284.6% Upside
Current Price
C$1.56
Last close
Targets are snapshotted when they change. Unchanged figures keep their original date. Not financial advice.
Wealth Awesome Price Forecast
WA ModelStatistical 90-day price range based on CRDL's historical volatility
30-Day Vol
71.8%
Annualized
90-Day Vol
63.7%
Annualized
Trend (90d)
+50.0%
Annualized drift
90d Mean
C$2.67
Expected price
| Horizon | Expected | 68% Range (1σ) |
|---|---|---|
| 30 trading days | C$2.37 | C$1.85 – C$3.03 |
| 60 trading days | C$2.51 | C$1.77 – C$3.57 |
| 90 trading days | C$2.67 | C$1.74 – C$4.09 |
Methodology: Range is calculated using 30-day realized volatility via geometric Brownian motion (log-normal model). 68% band = ±1σ, 95% band = ±2σ. This is a statistical model, not a prediction. Past volatility does not guarantee future results. Not financial advice.
Advertisement
Investor takeaway: Investors should remain cautious as Cardiol Therapeutics navigates a challenging market landscape, despite recent positive developments in its clinical trials.
Stock Down 5.91% in One Day
Cardiol Therapeutics' market cap now stands at CA$270.97 million following the drop in stock price.
Bull case
The company reached its Phase III MAVERIC enrollment target ahead of schedule, which could be a positive sign for future trial results and boost market confidence.
Bear case
The recent stock drop may indicate broader market concerns or investor skepticism about the company's ability to deliver on its promises, even with its recent achievements.
Market Reaction to Recent Developments
Advertisement
Despite hitting its Phase III MAVERIC trial enrollment target early, the stock's decline suggests that investors are weighing the risks in the biotech sector. This market reaction shows a cautious sentiment among investors, likely driven by uncertainty about the upcoming trial results.
Understanding the Financial Landscape
With a market cap of CA$270.97 million, Cardiol Therapeutics is in a competitive space. The recent stock performance could reflect broader market trends or specific investor concerns about the company's future profitability, especially given the lack of a profit margin and the absence of dividends.
Looking Ahead: What’s Next for Cardiol?
As Cardiol Therapeutics continues its clinical trials and financial strategies, investors will need to keep a close eye on upcoming announcements. The company's ability to turn trial successes into market confidence will be crucial for its stock performance in the near future.
Best next step
Keep exploring this topic
If you want to go deeper, these are the most useful follow-up pages and tools for this topic.
Broker comparison
Best trading platforms in Canada
Compare $0-commission brokers before you act on a ticker story.
Safe cash
Best GIC rates in Canada
If the story makes you want to de-risk, compare guaranteed rates next.
HISA roundup
Best high-interest savings accounts
Keep dry powder in a no-fee savings account instead of chequing.
TFSA room
Check TFSA contribution room
Shelter the next contribution before you buy.
Advertisement
Wealth Awesome
Timely coverage of Canadian stocks, earnings, dividends, and market movers for DIY investors. Stories are checked against exchange data and public filings.
View Full Profile →✅ Reviewed by Certified Financial Professionals
This content has been reviewed by CFA® charterholders and Certified Financial Planners (CFP®) with over a decade of experience in Canadian financial markets. All information is fact-checked against official Canadian sources and regulations.
Why these credentials matter: CFA® charterholders complete 900+ hours of rigorous study in investment analysis and ethics. CFP® professionals are held to the highest standards of financial planning competency and fiduciary duty in Canada.
⚠️ Professional Disclaimer
This content is for educational purposes only and should not be considered personalized financial advice. While our team brings professional expertise, individual circumstances vary. For personalized guidance, consult with a qualified financial advisor, tax professional, or mortgage specialist.
